GLP-1 Market
LLY $1179.27 ▲ +0.8% NVO $38.64 ▲ +1.2% PFE $28.28 ▲ +1.7% VKTX $28.51 ▲ +2.8% KLRA $11.61 ▲ +16.1% GPCR $25.54 ▼ -0.5% RHHBY $54.09 ▲ +1.3%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Nomlabofusp

Company
Larimar Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 10, 2026

Find a Clinical Trial Near Me

See recruiting studies for Nomlabofusp and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06447025

    An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

    Not yet reported Larimar Therapeutics, Inc. 85 participants Est. completion 2027-01 11 sites Stand-alone
    Other conditions: Friedreich Ataxia
    View official trial listing →
  • Recruiting NCT NCT07778836

    A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

    Not yet reported Larimar Therapeutics, Inc. 150 participants Est. completion 2029-12 4 sites Stand-alone
    Other conditions: Friedreich Ataxia, Friedreich's Ataxia
    View official trial listing →
  • Completed NCT NCT04176991

    Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

    Not yet reported Larimar Therapeutics, Inc. 28 participants Est. completion 2020-10-31 1 site Stand-alone
    Other conditions: Friedreich Ataxia
    View official trial listing →
  • Completed NCT NCT04519567

    Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

    Not yet reported Larimar Therapeutics, Inc. 27 participants Est. completion 2021-03-16 1 site Stand-alone
    Other conditions: Friedreich Ataxia
    View official trial listing →
  • Completed NCT NCT05579691

    A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

    Not yet reported Larimar Therapeutics, Inc. 28 participants Est. completion 2023-12-04 1 site Stand-alone
    Other conditions: Friedreich Ataxia
    View official trial listing →
  • Terminated NCT NCT06681766

    A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

    Not yet reported Larimar Therapeutics, Inc. 18 participants Est. completion 2025-04-27 1 site Stand-alone
    Other conditions: Friedreich Ataxia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Nomlabofusp, CTI-1601

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.